These findings suggest that PECAM EMPs may promote the apoptosis of HPMECs in COPD by de-activating the Akt pathway, and this effect can be attenuated, in part, through regulation by an antioxidant (EUK-134) (Figure 2). Here, AKT1 is linked to chronic obstructive pulmonary disease.